Organism: Homo sapiens
Gene: 39751_at
Selected probe(set): 218078_s_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of 39751_at (218078_s_at) across 6674 perturbations tested by GENEVESTIGATOR:

Relative Expression (log2-ratio):-3.3941765
Number of Samples:2 / 4

Experimental	expO kidney cancer study 1 (neoplasm, malignant; primary)
	Primary tumor tissue samples obtained from the kidney of patients with malignant neoplasm.
Control	expO kidney cancer study 1 (granular cell carcinoma; primary)
	Primary tumor tissue samples obtained from the kidney of patients with granular cell carcinoma.

Relative Expression (log2-ratio):2.53481
Number of Samples:4 / 207

Experimental	expO kidney cancer study 1 (granular cell carcinoma; primary)
	Primary tumor tissue samples obtained from the kidney of patients with granular cell carcinoma.
Control	expO kidney cancer study 1 (clear cell adenocarcinoma, NOS; primary)
	Primary tumor tissue samples obtained from the kidney of patients with clear cell adenocarcinoma (NOS).

Relative Expression (log2-ratio):2.4925137
Number of Samples:4 / 2

Experimental	oxyphilic adenoma study 1
	Tumor tissue samples from the kidney of patients with oxyphilic adenoma (renal oncocytoma).
Control	normal kidney tissue (fetal)
	Normal fetal kidney tissue samples.

Relative Expression (log2-ratio):2.418951
Number of Samples:18 / 2

Experimental	expO kidney cancer study 1 (renal cell carcinoma, chromophobe type; primary)
	Primary tumor tissue samples obtained from the kidney of patients with renal cell carcinoma, chromophobe type.
Control	expO kidney cancer study 1 (neoplasm, malignant; primary)
	Primary tumor tissue samples obtained from the kidney of patients with malignant neoplasm.

Relative Expression (log2-ratio):2.270402
Number of Samples:4 / 3

Experimental	oxyphilic adenoma study 1
	Tumor tissue samples from the kidney of patients with oxyphilic adenoma (renal oncocytoma).
Control	normal kidney tissue (adult)
	Normal adult kidney tissue samples.

Relative Expression (log2-ratio):2.2019672
Number of Samples:22 / 2

Experimental	expO kidney cancer study 1 (papillary adenocarcinoma, NOS; primary)
	Primary tumor tissue samples obtained from the kidney of patients with papillary adenocarcinoma (NOS).
Control	expO kidney cancer study 1 (neoplasm, malignant; primary)
	Primary tumor tissue samples obtained from the kidney of patients with malignant neoplasm.

Relative Expression (log2-ratio):-2.1975546
Number of Samples:2 / 4

Experimental	breast cancer study 8 (metastatic)
	Human metastatic infiltrating ductal carcinoma sample of the breast derived from lymph nodes of a female patient with breast cancer.
Control	normal breast tissue
	Normal human breast samples of healthy female individuals.

Relative Expression (log2-ratio):-2.1460476
Number of Samples:3 / 4

Experimental	expO kidney cancer study 1 (renal cell carcinoma, sarcomatoid; primary)
	Primary tumor tissue samples obtained from the kidney of patients with renal cell carcinoma, sarcomatoid.
Control	expO kidney cancer study 1 (granular cell carcinoma; primary)
	Primary tumor tissue samples obtained from the kidney of patients with granular cell carcinoma.

Relative Expression (log2-ratio):-2.1201868
Number of Samples:4 / 3

Experimental	lung cancer study 1 (PDX; large cell carcinoma, NOS; primary)
	Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary large cell carcinoma, NOS of the lung (subcutaneously implanted).
Control	lung cancer study 1 (PDX; basaloid carcinoma; primary)
	Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary basaloid carcinoma of the lung (subcutaneously implanted).

Relative Expression (log2-ratio):2.0202045
Number of Samples:5 / 2

Experimental	expO kidney cancer study 1 (renal cell carcinoma, NOS; primary)
	Primary tumor tissue samples obtained from the kidney of patients with renal cell carcinoma (NOS).
Control	expO kidney cancer study 1 (neoplasm, malignant; primary)
	Primary tumor tissue samples obtained from the kidney of patients with malignant neoplasm.